PDL BioPharma, Inc.

PDL BioPharma, Inc.

PDL BioPharma, Inc.

Overview
Date Founded

1986

Headquarters

34801 Campus Drive,Fremont, CA 94555

Type of Company

Public

Employees (Worldwide)

19

Industries

Biotechnology
Hospitals & Patient Services
Medical Support Services

Company Description

PDL BioPharma, Inc. produces and markets biopharmaceutical products. It focuses on intellectual property asset management, investing in new royalty bearing assets and maximizing the value of its patent portfolio and related assets. The company manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. PDL BioPharma was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Incline Village, NV.

Website
Executives & Employees

Chief Executive Officer

President

Chief Financial Officer & Vice President

Secretary, Vice President & General Counsel

Deputy General Counsel

Vice President, Finance & Chief Accounting Officer

Founder

Founder

Owner

Partner

Subscribe now to see full list of current and former executives
Board of Directors

President & Chief Executive Officer at S-G Management LLC

Executive Vice President & Chief Financial Officer at Incyte Corp.

Vice Chancellor, Business Development, Innovation & Partnerships at University of California - San Francisco

President, Chief Executive Officer & Director at Xeris Pharmaceuticals, Inc.

Former Secretary, Executive Vice President & General Counsel at Boston Scientific Corporation

Assistant Clinical Professor of Medicine in the Oncology Division of the Department of Medicine at UCSF School of Medicine

Chief Executive Officer at PDL BioPharma, Inc.

Subscribe now to see full list of current and former board members
Paths to PDL BioPharma, Inc.
Potential Connections via
Relationship Science
You
PDL BioPharma, Inc.
Owners & Shareholders
Details Hidden

Kestrel Investment Management Corp. is a value manager that focuses on investments in the stocks of companies that are undergoing voluntary restructurings. The firm's investment selection process is based on the use of cash flow and financial screens. Kestrel typically holds individual portfolio investments for 18 months to 3 years. They do not diversify solely to achieve industry or sector representation. Kestrel avoids stock market timing and macroeconomic forecasting, relying instead on identifying unrecognized microeconomic trends and misperceived factors. Kestrel seeks to remain fully-invested.

Details Hidden

SMH Capital Advisors (SMHCA) offers discretionary portfolio management services through three programs: the Separately Managed Account Program (SMA Program); the SMH Capital Investments Program (SMH Program); and the Institutional Program. In all three programs, clients’ assets are invested in various securities, including, but not limited to equity securities including common and preferred stock, including exchange-listed, over-the-counter, and foreign issuer securities; warrants; corporate debt securities; commercial paper; certificates of deposit; municipal securities; investment company securities, including mutual fund shares (including affiliated mutual funds); closed-end funds, ETFs; ADRs, REITS, publicly traded business development companies, US government and government agency securities; high yield corporate bonds; and CMOs.

Details Hidden

Nine Chapters Capital Management (NCCM) employs a range of quantitative tools to identify profit opportunities, construct portfolios in a cost-efficient manner, and manage the overall risk of the portfolio consistent with the goal of producing risk-adjusted returns. The firm uses proprietary portfolio construction, risk management and execution tools to construct a portfolio of long and short positions in equities and other liquid instruments and to control its overall risk by hedging certain systematic risks. NCCM manages alternative investment vehicles that take long and short positions primarily in equities and other liquid financial instruments by combining multiple trading strategies designed to generate return through long-term and short-term market price patterns. The funds' main objective is to achieve consistent and risk-adjusted investment returns through research-driven and quantitative methods that seek to maximize the ratio of returns to risk. While the funds tend to focus on U.S. equities and related instruments, they may in the future expand to other regions, including but not limited to Europe, Asia Pacific and Latin America, including certain emerging markets. NCCM usees proprietary portfolio construction, risk management and execution tools to construct a portfolio of long and short positions in equities and other liquid instruments and to control its overall risk by hedging certain systematic risks. The funds also trade currency forwards to hedge currency risk. The funds generally employ leverage in pursuing their investment strategies.

Subscribe now to see full details
Recent Transactions
Details Hidden

purchases Abbott Biotherapeutics Corp. from PDL BioPharma, Inc.

Details Hidden

purchases PDL BioPharma, Inc.

Subscribe now to see full list of recent transations
Transaction Advisors
Auditor

Advised on purchases PDL BioPharma, Inc.

Legal Advisor

Advised on purchases PDL BioPharma, Inc.

Investment Advisor

Advised on purchases Abbott Biotherapeutics Corp. from PDL BioPharma, Inc.

Subscribe now to see 1+ more transaction advisors
Subscribe now to see transaction advisors for over 2.5 million organizations
Advisors & Consultants
Subscribe now to see advisors & consultants for over 2.5 million organizations
Legal Advisor

Partner at Irell & Manella LLP

Legal Advisor

Partner at Weil, Gotshal & Manges LLP

Advisor

Partner at Centerview Partners LLC

Subscribe now to see 2+ more consultants & advisors
Clients

McKesson is dedicated to delivering the vital medicines, medical supplies and information technologies that enable the health care industry to provide patients better, safer care. McKesson is made up of many businesses, all serving the health care industry. Our businesses fall into one of two primary categories: Distribution solutions. We are the largest pharmaceutical distributor in North America, distributing one-third of the medicines used every day. As one of the leading pharmaceutical companies, we supply more than 40,000 U.S. pharmacy locations, from Wal-Mart to the Department of Veterans Affairs to community pharmacies and hospitals. McKesson is also one of the leading medical supply companies and distributes medical-surgical supplies and homecare supplies. Healthcare Technology solutions. We develop and install healthcare information technology systems that eliminate the need for paper prescriptions and paper medical records. Our software and hardware are used in more than 70% of the nation's hospitals with more than 200 beds. Our hospital information system solutions include electronic health record system (EHR) and clinical decision support system such as Interqual. McKesson's Healthcare IT division also serves diverse areas within the health industry by offering solutions such as pharmacy automation and medical claims management software. McKesson publicly traded on NYSE under MCK Businesses Serving our customers—pharmacies, medical and pharmaceutical manufacturers, hospitals, and insurers—as the health care industry evolves is our primary goal. We have business lines to automate processes from medical supplies packaging to claims management, and revenue cycle management to medical imaging. McKesson's long history in pharmaceutical industry History McKesson has a long history in health care. We’ve been a trusted provider of medical supplies and goods for more than 175 years.

Cardinal Health, Inc. is a healthcare services company providing pharmaceutical and medical products. It operates through the Pharmaceutical and Medical segments. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, over-the-counter healthcare and consumer products in the United States, and operates nuclear pharmacies and cyclotron facilities, provides pharmacy management services to hospitals as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers and payers, provides services to healthcare companies supporting the development, marketing, and distribution of specialty pharmaceutical products, and repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment distributes a broad range of medical, surgical and laboratory products and provides services to hospitals, ambulatory surgery centers, clinical laboratories and other healthcare providers in the United States, Canada and China; as well as manufactures, sources and develops own Cardinal Health brand medical and surgical products, which are sold in the United States, Canada, Europe and other regions internationally, and provides post-acute care management and transition services and software to hospitals, other healthcare providers and payers. The company was founded by Robert D. Walter in 1971 and is headquartered in Dublin, OH.

Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Subscribe now to see 3 more clients
Subscribe now to see clients for over 2.5 million organizations
Key Stats and Financials As of 2016
Market Capitalization
$369M
Total Enterprise Value
$343M
Earnings Per Share
$0.39
Revenue
$240M
Net Profit
$63.6M
Total Debt
$232M
Total Equity
$755M
EBITDA
$191M
EBITDAMargin
79.88%
Enterprise Value Sales
1.43x
Enterprise Value EBITDAOperating
1.79x
TEVNet Income
5.39x
Debt TEV
0.68x
Three Year Compounded Annual Growth Rate Of Revenue
-18.6%
Five Year Compounded Annual Growth Rate Of Revenue
-7.92%
Subscribe now to see full financial details
Non-Profit Donations & Grants
Subscribe now to see 2 more non-profit donations & grants